Phio Pharmaceuticals Corp. (PHIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150K 300K 450K Q2 '13: 375K Q3 '13: 410K Q4 '13: 399K Q1 '14: 375K Q4 '15: 34K Q1 '16: 10K Q2 '16: 19K Q3 '16: 19K Q4 '16: 19K Q1 '17: 9K Q2 '17: 0 Q3 '17: 0 Q4 '17: 15K Q1 '18: 38K Q2 '18: 96K Q3 '18: 153K Q4 '18: 138K Q1 '19: 136K Q2 '19: 78K Q3 '19: 21K Q4 '19: 21K Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q2 '13 Q4 '15 Q4 '16 Q4 '17 Q4 '18 Q4 '19 Q4 '20

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q2 '12: -14.2M Q3 '12: -13.8M Q4 '12: -13M Q1 '13: -25.5M Q2 '13: -19.8M Q3 '13: -20.1M Q4 '13: -20.9M Q1 '14: -8.8M Q2 '14: -8.9M Q3 '14: -9M Q4 '14: -8.8M Q1 '15: -9.5M Q2 '15: -9.6M Q3 '15: -9.9M Q4 '15: -10.2M Q1 '16: -9.5M Q2 '16: -9.6M Q3 '16: -9.3M Q2 '17: -14.2M Q3 '17: -14.4M Q4 '17: -14.1M Q1 '18: -9.2M Q2 '18: -8.6M Q3 '18: -7.6M Q4 '18: -7.4M Q1 '19: -7.3M Q2 '19: -7.4M Q3 '19: -8.1M Q4 '19: -9M Q1 '20: -9.2M Q2 '20: -8.8M Q3 '20: -9M Q4 '20: -8.8M Q1 '21: -10.1M Q2 '21: -11.1M Q3 '21: -12.5M Q4 '21: -13.5M Q1 '22: -12.5M Q2 '22: -12.3M Q3 '22: -12.2M Q4 '22: -11.5M Q1 '23: -12.4M Q2 '23: -12.4M Q3 '23: -11.7M Q4 '23: -10.8M Q1 '24: -9.4M Q2 '24: -8.8M Q3 '24: -7.6M Q4 '24: -7.4M Q1 '25: -7M Q2 '25: -7.4M Q3 '25: -8.4M Q4 '25: -9.2M Q1 '26: -11.5M Q2 '26: -13.5M Q3 '13 Q2 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-27M -18M -9M 0 9M 18M 27M Q4 '11: -2.5M Q1 '12: -8.3M Q2 '12: -14M Q3 '12: -13.6M Q4 '12: -12.9M Q1 '13: -25.4M Q2 '13: -19.7M Q3 '13: -20.1M Q4 '13: -20.9M Q1 '14: -8.8M Q2 '14: -8.9M Q3 '14: -9M Q4 '14: -8.8M Q1 '15: -9.5M Q2 '15: -9.6M Q3 '15: -9.9M Q4 '15: -10.2M Q1 '16: -9.5M Q2 '16: -9.6M Q3 '16: -9.3M Q2 '17: -12.5M Q3 '17: -12.8M Q4 '17: -12.5M Q1 '18: -9.2M Q2 '18: -8.6M Q3 '18: -7.6M Q4 '18: -7.4M Q1 '19: -7.2M Q2 '19: -7.4M Q3 '19: -8M Q4 '19: -8.9M Q1 '20: -9.1M Q2 '20: -8.8M Q3 '20: -9M Q4 '20: -8.8M Q1 '21: -9.8M Q2 '21: -10.9M Q3 '21: -12.3M Q4 '21: -13.3M Q1 '22: -12.5M Q2 '22: -12.4M Q3 '22: -12.2M Q4 '22: -11.5M Q1 '23: -12.4M Q2 '23: -12.5M Q3 '23: -11.7M Q4 '23: -10.8M Q1 '24: -9.4M Q2 '24: -8.7M Q3 '24: -7.4M Q4 '24: -7.2M Q1 '25: -6.8M Q2 '25: -7.1M Q3 '25: -8M Q4 '25: -8.7M Q1 '26: -10.9M Q2 '26: -12.9M Q4 '11 Q4 '13 Q4 '15 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '12: -5.1M Q1 '13: -5M Q2 '13: -5.6M Q3 '13: -6.1M Q4 '13: -6.3M Q1 '14: -7.6M Q2 '14: -7.5M Q3 '14: -7.6M Q4 '14: -7.8M Q1 '15: -7.3M Q2 '15: -7.1M Q3 '15: -7.3M Q4 '15: -7.3M Q1 '16: -8.3M Q2 '16: -8.3M Q3 '16: -8M Q4 '16: -7.8M Q1 '17: -7.6M Q2 '17: -8.1M Q3 '17: -8.7M Q4 '17: -9.5M Q1 '18: -8.6M Q2 '18: -8.2M Q3 '18: -8M Q4 '18: -7.5M Q1 '19: -7.8M Q2 '19: -7.9M Q3 '19: -7.8M Q4 '19: -8.6M Q1 '20: -8.6M Q2 '20: -8.7M Q3 '20: -8.7M Q4 '20: -8.8M Q1 '21: -9.9M Q2 '21: -11.1M Q3 '21: -12M Q4 '21: -11.9M Q1 '22: -12.1M Q2 '22: -11.2M Q3 '22: -11.9M Q4 '22: -12.1M Q1 '23: -11.4M Q2 '23: -11.7M Q3 '23: -11.1M Q4 '23: -10.7M Q1 '24: -10.1M Q2 '24: -9.1M Q3 '24: -8.1M Q4 '24: -7.1M Q1 '25: -6.4M Q2 '25: -7.1M Q3 '25: -7.3M Q4 '25: -8M Q1 '26: -10.7M Q2 '26: -12.2M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q2 '15: -7.2M Q3 '15: -7.4M Q4 '15: -7.4M Q3 '17: -8.9M Q4 '17: -9.7M Q1 '18: -8.8M Q2 '18: -8.2M Q3 '18: -8M Q4 '18: -7.5M Q1 '19: -7.8M Q2 '19: -7.9M Q3 '19: -7.9M Q4 '20: -8.8M Q1 '21: -9.9M Q2 '21: -11.1M Q3 '21: -12.1M Q4 '21: -11.9M Q1 '22: -12.2M Q2 '22: -11.4M Q3 '22: -12M Q4 '22: -12.2M Q1 '23: -11.4M Q2 '23: -11.7M Q3 '23: -11.1M Q4 '23: -10.8M Q1 '24: -10.1M Q2 '24: -9.1M Q3 '24: -8.1M Q4 '24: -7.1M Q1 '25: -6.4M Q2 '25: -7.1M Q3 '25: -7.3M Q4 '25: -8M Q1 '26: -10.7M Q2 '26: -12.2M Q4 '17 Q1 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q1 '21: 10.7M Q2 '21: 13.5M Q3 '21: 13.5M Q1 '22: 1.1M Q2 '22: 1.1B Q3 '22: 1.1M Q1 '23: 1.1M Q2 '23: 192.1K Q3 '23: 271.1K Q1 '24: 4.6M Q2 '24: 510.2K Q3 '24: 990K Q1 '25: 4.3M Q2 '25: 4.8M Q3 '25: 5.5M Q1 '26: 11.6M Q2 '26: 11.6M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-75.00 -50.00 -25.00 0.00 25.00 50.00 75.00 Q4 '11: -0.28 Q1 '12: -0.19 Q2 '12: -4.27 Q3 '12: -4.78 Q4 '12: -5.03 Q1 '13: -7.75 Q2 '13: -4.01 Q3 '13: -3.75 Q4 '13: -3.69 Q1 '14: -1.25 Q2 '14: -1.09 Q3 '14: -0.96 Q4 '14: -0.82 Q1 '15: -1.82 Q2 '15: -2.09 Q3 '15: -2.30 Q4 '15: -2.54 Q1 '16: -4.63 Q2 '16: -7.51 Q3 '16: -10.49 Q2 '17: -10.36 Q3 '17: -11.07 Q4 '17: -5.63 Q1 '18: -3.88 Q2 '18: -3.22 Q3 '18: -2.51 Q4 '18: -57.62 Q1 '19: -62.43 Q2 '19: -66.59 Q3 '19: -70.78 Q4 '19: -19.49 Q1 '20: -15.11 Q2 '20: -10.83 Q3 '20: -6.70 Q4 '20: -2.48 Q1 '21: -1.47 Q2 '21: -1.33 Q3 '21: -1.21 Q4 '21: -12.45 Q1 '22: -14.47 Q2 '23: -21.96 Q3 '23: -29.07 Q4 '23: -28.15 Q1 '24: -25.47 Q2 '24: -15.82 Q3 '24: -7.11 Q4 '24: -6.48 Q1 '25: -6.42 Q2 '25: -3.25 Q3 '25: -2.15 Q4 '25: -1.45 Q1 '26: -1.38 Q2 '26: -1.29 Q3 '12 Q2 '14 Q1 '16 Q2 '18 Q1 '20 Q4 '21 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.